Clinical and molecular characterization of early‐onset colorectal cancer
Alexandra N. Willauer(The University of Texas MD Anderson Cancer Center), Jonathan M. Loree(University of British Columbia), Van K. Morris(The University of Texas MD Anderson Cancer Center), Winston W. Huh(The University of Texas MD Anderson Cancer Center), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Russell R. Broaddus(University of North Carolina at Chapel Hill), David G. Menter(The University of Texas MD Anderson Cancer Center), Yusha Liu(Rice University), Andrea Hayes‐Jordan(The University of Texas MD Anderson Cancer Center), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Allan Andresson Lima Pereira(The University of Texas MD Anderson Cancer Center), Michael Lam(The University of Texas MD Anderson Cancer Center), Michael J. Overman(The University of Texas MD Anderson Cancer Center), Jeffrey S. Morris(The University of Texas MD Anderson Cancer Center), Scott Kopetz(The University of Texas MD Anderson Cancer Center)
Cited by 361
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
|Journal of Clinical Oncology|2023|882